- Home
- QCLS vs NTRB Comparison
QCLS vs NTRB Comparison
Compare QCLS & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QCLS | NTRB |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | 2 | 3 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 35.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QCLS | NTRB |
|---|---|---|
| Price | $4.03 | $3.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 396.5K | 9.8K |
| Earning Date | 04-15-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $2.90 |
| 52 Week High | $8.17 | $11.68 |
Technical Indicators
Market Signals| Indicator | QCLS | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 27.34 |
| Support Level | $3.86 | N/A |
| Resistance Level | $4.66 | $3.67 |
| Average True Range (ATR) | 0.28 | 0.17 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 53.68 | 0.00 |
Price Performance
Historical ComparisonAbout QCLS Q/C Technologies Inc.
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.